



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>Sent 9/29/05</i>		Complete if Known	
		Application No.	10/633,843
		Filing Date	August 4, 2003
		First Named Inventor	C. Frank Bennett, <i>et al.</i>
		Art Unit	1645 1635
Examiner Name	Unknown T. Gibbs		
Attorney Docket Number	23546-10350 (ISPH-0756)		
Sheet	1	of	21

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Document No. Number – Kind Code ² (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
JLH	A1	US-5,849,290	12/1998	Brown, et al.
	A2	US-5,994,076	11/1999	Chenchik et al.
	A3	US-6,077,833	06/2000	Bennett et al.
	A4	US-5,801,154	09/1998	Baracchini et al.
	A5	US-5,998,148	12/1999	Bennett et al.

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ³
JLH	B1	Misra et al. Drug delivery to the central nervous system: a review. J. Phar Pharmaceut Sci, 2003 Vol. 6(2) pages 252-273 Elsevier	
	B2	Grzanna et al. Intrastriatal and intraventricular injections of oligodeoxynucleotides in the rat brain: tissue penetration, intracellular distribution and c-fos antisense effects. Molecular Brain Research, 1998 Vol. 63, pages 35-52. Elsevier	
	B3	Green et al. Antisense Oligonucleotides: An Evolving Technology for the Modulation Of Gene Expression in Human Disease. Antisense Therapy in Human Disease (2000) Vol. 191: pages 93-105. Elsevier Science Inc..	
	B4	Jen et al. Suppression of Gene Expression by Targeted Disruption Of Messenger RNA: Available Options and Current Strategies. Stem Cells (2000) Vol. 18; pages 307-319. AlphaMed Press.	
	B5	Branch et al. A Good Antisense Molecule is Hard to Find. TIBS (1998) Vol. 23, pages 45-50. Elsevier Science LTD.	
JLH	B6	Crooke, ST, Basic Principles Of Antisense Therapeutics. Antisense Research An Application (1998). Chapter 1 Springer-Verlag, New York.	

Examiner Signature	<i>Leua C. JLO</i>	Date Considered	3/27/06
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

23546/10350/SF/5151333.1